Today: 12 April 2026
Subscribe
Browse Category

NASDAQ:VRTX 27 June 2025 - 28 March 2026

Vertex Pharmaceuticals Stock Falls 4.6% After FDA Label Warning Hits Alyftrek, Trikafta

Vertex Pharmaceuticals Stock Falls 4.6% After FDA Label Warning Hits Alyftrek, Trikafta

Vertex Pharmaceuticals shares fell 4.6% to $433.07 Friday after updated U.S. safety warnings on its cystic fibrosis drugs Alyftrek and Trikafta cited reports of serious neuropsychiatric events. The new labels advise close monitoring for symptoms such as depression and suicidal thoughts. Vertex expects 2026 revenue to remain heavily dependent on cystic fibrosis treatments, despite ongoing efforts to expand its pipeline.
28 March 2026
··
Vertex stock jumps nearly 6% on Oppenheimer upgrade as traders size up new drug pipeline

Vertex stock jumps nearly 6% on Oppenheimer upgrade as traders size up new drug pipeline

Vertex shares jumped 5.7% to $491.47 Friday after Oppenheimer upgraded the stock, citing growth plans beyond cystic fibrosis. The company set 2026 revenue guidance at up to $13.1 billion, with at least $500 million expected from new products. Vertex highlighted gene-editing, pain, and kidney therapies in its outlook. U.S. markets close Monday for Presidents Day.
14 February 2026
··
Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex Pharmaceuticals shares rose 4.31% to $461.14, extending gains for a third session with trading volume above the 50-day average. The company will report fourth-quarter and full-year 2025 results after the U.S. market closes on Feb. 12, followed by a conference call. Director Bruce I. Sachs received 107.088 deferred stock units, according to a Jan. 15 regulatory filing.
22 January 2026
···
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
Vertex Pharmaceuticals (VRTX) Stock Week Ahead: Holiday-Shortened Trading, New Gene-Therapy Data, and Fresh Analyst Targets (Dec. 22–26, 2025)

Vertex Pharmaceuticals (VRTX) Stock Week Ahead: Holiday-Shortened Trading, New Gene-Therapy Data, and Fresh Analyst Targets (Dec. 22–26, 2025)

Vertex Pharmaceuticals shares closed at $456.20 on Dec. 19, up 2% with higher-than-usual trading volume ahead of a holiday-shortened week. New data for CASGEVY showed children ages 5–11 remained free of crises or transfusions for at least 12 months, but one patient died from busulfan-related complications. Vertex plans global filings in 2026. Morgan Stanley upgraded the stock to Overweight in December.
22 December 2025
Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

Vertex Pharmaceuticals reported new pediatric results for Casgevy on Dec. 6, showing all four children with severe sickle cell disease were free of vaso-occlusive crises for at least 12 months. Twelve pediatric beta thalassemia patients remained transfusion-free for at least a year. Vertex plans global regulatory filings in 2026. One TDT patient died from busulfan-related complications.
21 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals closed up 1.97% at $456.20 Friday, ending a three-day slide on volume of about 5.56 million shares, far above its 50-day average. After-hours trading was quiet, with the stock quoted near $456.49 as of 7:40 p.m. ET. No major company news drove the move; trading reflected broad market gains and heavy year-end positioning.
20 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals shares closed Friday at $452.04, up 1.37%, extending a three-day rally but still 13% below the March high of $519.68. Trading volume topped 1.6 million shares, above the 50-day average. A Morgan Stanley upgrade and optimism over Vertex’s kidney disease pipeline have driven recent swings. New pediatric data for gene-editing therapy Casgevy drew attention at the ASH meeting.
15 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Vertex Pharmaceuticals shares closed at $452.04 Friday, up 2.26% for the week after rebounding from early losses. The move followed new pediatric data for CASGEVY, showing children ages 5–11 with sickle cell disease remained crisis-free for at least 12 months. Vertex plans global regulatory submissions in 2026. One beta thalassemia patient died from pre-transplant chemotherapy complications.
13 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals shares closed at $455.48 on December 5, 2025, valuing the company at about $115–116 billion. New data presented December 6 showed CASGEVY gene therapy achieved 12-month crisis- and transfusion-free outcomes in children 5–11 with sickle cell disease and beta thalassemia, though one pediatric patient died from transplant complications. Vertex plans global regulatory filings for this age group in early 2026.
7 December 2025
····
Martian Life Clues, Hawking Vindication, and More – Science News Roundup (Sept 11–12, 2025)

Martian Life Clues, Hawking Vindication, and More – Science News Roundup (Sept 11–12, 2025)

NASA’s Perseverance rover detected Martian mudstone with minerals resembling those formed by microbes on Earth, raising the possibility of ancient life, though not confirmed. Physicists confirmed Hawking’s black hole area theorem using data from a 2025 black hole merger. A unique gamma-ray burst lasting up to 1,000 times longer than normal puzzled astronomers. Stem-cell therapy let most type 1 diabetes patients stop insulin for over a year.
12 September 2025
·
Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, missing its main goal and deepening setbacks from its $5.4 billion Global Blood Therapeutics acquisition. In contrast, Pfizer and Merck’s Padcev-Keytruda combo improved survival in muscle-invasive bladder cancer. Novo Nordisk’s Wegovy won FDA approval for treating metabolic dysfunction-associated steatohepatitis.
17 August 2025
······
June 2025 Science Breakthroughs and Projects: Medicine, Space, Climate, AI & More

June 2025 Science Breakthroughs and Projects: Medicine, Space, Climate, AI & More

Cancer cells siphon mitochondria from nerve cells through microscopic tubes, aiding metastasis, a Nature study found. Tumor DNA was detected in blood years before diagnosis, offering early screening potential. Casgevy, a CRISPR-based sickle-cell therapy, has treated over 90 patients since late 2024. NASA’s James Webb Space Telescope directly imaged exoplanet TWA-7b, a Saturn-mass gas giant.
28 June 2025
···
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

The FDA approved Abeona’s Zevaskyn, the first cell-based gene therapy for RDEB, in April 2025, with launch set for Q3 at $3.1 million. Vertex’s CRISPR therapy Casgevy generated $2 million in Q3 2024. Novo Holdings acquired Catalent for $16.5 billion in January 2025 to secure GLP-1 drug manufacturing. Johnson & Johnson bought Intra-Cellular Therapies for $14.6 billion, expanding its neuroscience portfolio.
27 June 2025
···········

Stock Market Today

  • Gamma Communications Surges 16% on Takeover Talks, Posing Portfolio Challenges
    April 12, 2026, 4:26 AM EDT. Gamma Communications (LSE:GAMA) surged 16.6% amid takeover speculation, despite being down 29% over the past year. The UK cloud communications provider is in talks with potential bidders, pushing its share price above the author's buy-in level and complicating investment plans. While the pending sale could bring a premium, a bid below purchase price would mean a loss for investors. Gamma, positioned to benefit from the UK's copper network shutdown, faces stiff competition from giants like Microsoft but holds advantages through owning telecom infrastructure. The takeover buzz places the stock in uncertain territory, creating a dilemma about future value and portfolio impact.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 12.04.2026

12 April 2026
Futu Holdings (FUTU) rose 10.2% in the past week but trades 13.4% below its January level. Shares closed at $154.50, while analysts estimate intrinsic value at $245.48. The company posted a 92.2% return over 12 months. Valuation models indicate earnings exceed risk costs, supporting long-term growth projections.
India F-35 Deal Hits Pause: Lockheed Martin Says No Direct Talks, U.S. Door Still Open

India F-35 Deal Hits Pause: Lockheed Martin Says No Direct Talks, U.S. Door Still Open

11 April 2026
Lockheed Martin said it is not in direct talks with India over the F-35, clarifying that any approach must go through official U.S. and Indian channels under the Foreign Military Sales process. Indian officials confirmed no formal discussions on acquiring the F-35 have begun. India recently approved a $40 billion military upgrade, including other fighter jets, while Lockheed’s F-21 remains in a separate competition.
Why SNOW Stock Is Falling Again: Snowflake Nears 52-Week Low as AI Worries Hit Software

Why SNOW Stock Is Falling Again: Snowflake Nears 52-Week Low as AI Worries Hit Software

11 April 2026
Snowflake shares fell 8.4% to $121.11 on Friday after an 11.7% drop Thursday, as investors sold off software stocks amid concerns over new AI tools from Anthropic and OpenAI. The stock now trades just above its 52-week low. The S&P 500 Software and Services Index is down 25.5% for the year. Snowflake reported fourth-quarter product revenue of $1.23 billion, up 30% from a year earlier.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 11:59 PM EDT DocuSign Stock Review: Is the 42% Yearly Drop a Buying Opportunity? April 11, 2026, 11:59 PM EDT. DocuSign (DOCU) shares have fallen 42.3% over the past year, raising questions about their value. Despite recent weakness, a Discounted Cash Flow (DCF) analysis suggests the stock is **68.1% undervalued**, with estimated intrinsic value around $134.42 versus a current price near $42.89. The DCF model projects growing free cash flows from $990 million in 2026 to $1.37 billion by 2029. Investors remain cautious amid evolving software spending trends
Go toTop